Adjuvant Radiochemotherapy of Stage II and III Rectal Adenocarcinoma: Role of CEA and CA 19-9

Background: This analysis was undertaken to evaluate the impact of pre-radiotherapy CEA and CA 19-9 values on clinical outcome of locally advanced rectal cancer. Patients and Methods: Retrospective data were collected from patients (n=203) with UICC stage II and III rectal adenocarcinomas, who under...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2005-05, Vol.25 (3A), p.1787-1793
Main Authors: WEISSENBERGER, Christian, VON PLEHN, Georg, OTTO, Florian, BARKE, Annette, MOMM, Felix, GEISSLER, Michael
Format: Article
Language:English
Subjects:
Adenocarcinoma - blood
Adenocarcinoma - drug therapy
Adenocarcinoma - radiotherapy
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers, Tumor - blood
CA-19-9 Antigen - blood
Carcinoembryonic Antigen - blood
Chemotherapy, Adjuvant
Combined Modality Therapy
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Middle Aged
Radiotherapy, Adjuvant
Rectal Neoplasms - blood
Rectal Neoplasms - drug therapy
Rectal Neoplasms - radiotherapy
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: This analysis was undertaken to evaluate the impact of pre-radiotherapy CEA and CA 19-9 values on clinical outcome of locally advanced rectal cancer. Patients and Methods: Retrospective data were collected from patients (n=203) with UICC stage II and III rectal adenocarcinomas, who underwent low anterior or abdominoperineal resection and received post-operative or pre-operative radiochemotherapy from January 1989 until July 2002. The rates of survival and distant and local recurrences were evaluated using Kaplan-Meier survival analysis, Log-rank test and Cox's proportional hazards (median follow-up 8 years). Multivariate analysis was used to assess the prognostic value of CEA and CA 19-9. Results: The 5-year actuarial rates for patients with normal (n=118) and elevated (n=88) CEA values were as follows: overall survival 62.4% and 32.0% (p
ISSN:0250-7005
1791-7530